on Mallia Innovations
Mallia Aesthetics Begins Studies on sCD83-Based Serums
Mallia Aesthetics GmbH has initiated two consumer studies to test the efficacy of their hormone-free serums, 8T3 Essentials Hair Serum and 8T3 Essentials Lash & Brow Serum, both based on the sCD83 protein variant MAL-838. These serums are designed to stimulate hair and eyelash growth.
The study on 8T3 Essentials Hair Serum is set over six months, focusing on hair density and thickness among male participants, using detailed image analysis. Meanwhile, the study for 8T3 Essentials Lash & Brow Serum spans twelve weeks, assessing effects on eyelash length, volume, and thickness. Results for the latter are anticipated by fall 2025.
MAL-838, the active ingredient, is derived from sCD83, known for its immunomodulatory and anti-inflammatory attributes. This innovation represents a potential breakthrough in localized hair growth treatments with minimal side effects.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Mallia Innovations news